Baral, S., Sifakis, F., Cleghorn, F. & Beyrer, C. Elevated threat for HIV an infection amongst males who’ve intercourse with males in low- and middle-income international locations 2000-2006: a scientific overview. PLoS Med. 4, e339 (2007).
Harmon, T. M. et al. Exploring the potential well being impression and cost-effectiveness of AIDS vaccine inside a complete HIV/AIDS response in low- and middle-income international locations. PLoS ONE 11, e0146387 (2016).
Stover, J. et al. How can we get near zero? The potential contribution of biomedical prevention and the funding framework in direction of an efficient response to HIV. PLoS ONE 9, e111956 (2014).
Denning, P. H. & Campsmith, M. L. Unprotected anal intercourse amongst HIV-positive males who’ve a gentle male intercourse accomplice with detrimental or unknown HIV serostatus. Am. J. Public Well being 95, 152–158 (2005).
Brandtzaeg, P., Farstad, I. N. & Haraldsen, G. Regional specialization within the mucosal immune system: primed cells don’t at all times house alongside the identical observe. Immunol. Right now 20, 267–277 (1999).
Cesta, M. F. Regular construction, perform, and histology of mucosa-associated lymphoid tissue. Toxicol. Pathol. 34, 599–608 (2006).
Kunisawa, J., Fukuyama, S. & Kiyono, H. Mucosa-associated lymphoid tissues within the aerodigestive tract: their shared and divergent traits and their significance to the orchestration of the mucosal immune system. Curr. Mol. Med. 5, 557–572 (2005).
Barnett, S. W. et al. Safety of macaques in opposition to vaginal SHIV problem by systemic or mucosal and systemic vaccinations with HIV-envelope. AIDS 22, 339–348 (2008).
Zhou, Q. et al. Comparative analysis of oral and intranasal priming with replication-competent adenovirus 5 host vary mutant (Ad5hr)-simian immunodeficiency virus (SIV) recombinant vaccines on immunogenicity and protecting efficacy in opposition to SIVmac251. Vaccine 25, 8021–8035 (2007).
Jones, A. T. et al. HIV-1 vaccination by needle-free oral injection induces sturdy mucosal immunity and protects in opposition to SHIV problem. Nat. Commun. 10, 798 (2019).
Curtis, A. D. 2nd et al. Oral coadministration of an intramuscular DNA/modified vaccinia Ankara vaccine for simian immunodeficiency virus is related to higher management of an infection in orally uncovered toddler macaques. AIDS Res. Hum. Retroviruses 35, 310–325 (2019).
Manrique, M. et al. Resistance to an infection, early and chronic suppression of simian immunodeficiency virus SIVmac251 viremia, and important discount of tissue viral burden after mucosal vaccination in feminine rhesus macaques. J. Virol. 88, 212–224 (2014).
Aarntzen, E. H. et al. Vaccination with mRNA-electroporated dendritic cells induces sturdy tumor antigen-specific CD4+ and CD8+ T cells responses in stage III and IV melanoma sufferers. Clin. Most cancers Res. 18, 5460–5470 (2012).
Barth, R. J. Jr. et al. A randomized trial of ex vivo CD40L activation of a dendritic cell vaccine in colorectal most cancers sufferers: tumor-specific immune responses are related to improved survival. Clin. Most cancers Res. 16, 5548–5556 (2010).
Bol, Ok. F. et al. Intranodal vaccination with mRNA-optimized dendritic cells in metastatic melanoma sufferers. Oncoimmunology 4, e1019197 (2015).
Schwaab, T. et al. Scientific and immunologic results of intranodal autologous tumor lysate-dendritic cell vaccine with Aldesleukin (Interleukin 2) and IFN-{alpha}2a remedy in metastatic renal cell carcinoma sufferers. Clin. Most cancers Res. 15, 4986–4992 (2009).
Lambert, L. A. et al. Intranodal immunization with tumor lysate-pulsed dendritic cells enhances protecting antitumor immunity. Most cancers Res. 61, 641–646 (2001).
Bedrosian, I. et al. Intranodal administration of peptide-pulsed mature dendritic cell vaccines ends in superior CD8+ T-cell perform in melanoma sufferers. J. Clin. Oncol. 21, 3826–3835 (2003).
Fouda, G. G. et al. Systemic administration of an HIV-1 broadly neutralizing dimeric IgA yields mucosal secretory IgA and virus neutralization. Mucosal. Immunol. 10, 228–237 (2017).
Mascola, J. R. et al. Safety of macaques in opposition to vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat. Med. 6, 207–210 (2000).
Shingai, M. et al. Passive switch of modest titers of potent and broadly neutralizing anti-HIV monoclonal antibodies block SHIV an infection in macaques. J. Exp. Med. 211, 2061–2074 (2014).
Haynes, B. F. et al. Immune-correlates evaluation of an HIV-1 vaccine efficacy trial. N. Engl. J. Med. 366, 1275–1286 (2012).
Zolla-Pazner, S. et al. Evaluation of V2 antibody responses induced in vaccinees within the ALVAC/AIDSVAX HIV-1 vaccine efficacy trial. PLoS ONE 8, e53629 (2013).
Zolla-Pazner, S., Alvarez, R., Kong, X. P. & Weiss, S. Vaccine-induced V1V2-specific antibodies management and or shield in opposition to an infection with HIV, SIV and SHIV. Curr. Opin. HIV AIDS 14, 309–317 (2019).
Schifanella, L. et al. ALVAC-HIV B/C candidate HIV vaccine efficacy depending on neutralization profile of problem virus and adjuvant dose and kind. PLoS Pathog. 15, e1008121 (2019).
Vaccari, M. et al. HIV vaccine candidate activation of hypoxia and the inflammasome in CD14(+) monocytes is related to a decreased threat of SIV(mac251) acquisition. Nat. Med. 24, 847–856 (2018).
Vaccari, M. et al. Adjuvant-dependent innate and adaptive immune signatures of threat of SIVmac251 acquisition. Nat. Med. 22, 762–770 (2016).
Hessell, A. J. et al. Multimeric epitope-scaffold HIV vaccines goal V1V2 and differentially tune polyfunctional antibody responses. Cell Rep. 28, 877–895 e876 (2019).
Jones, A. T. et al. A Trimeric HIV-1 envelope gp120 immunogen induces potent and broad anti-V1V2 loop antibodies in opposition to HIV-1 in rabbits and rhesus macaques. J. Virol. 92, https://doi.org/10.1128/JVI.01796-17 (2018).
Malherbe, D. C. et al. Mixture adenovirus and protein vaccines stop an infection or cut back viral burden after heterologous clade C simian-human immunodeficiency virus mucosal problem. J. Virol. 92, https://doi.org/10.1128/JVI.01092-17 (2018).
Weiss, S. et al. Differential V2-directed antibody responses in non-human primates contaminated with SHIVs or immunized with numerous HIV vaccines. Nat. Commun. 13, 903 (2022).
Singh, S. et al. Management of heterologous simian immunodeficiency virus SIVsmE660 an infection by DNA and protein coimmunization regimens mixed with completely different toll-like-receptor-4-based adjuvants in macaques. J. Virol. 92, https://doi.org/10.1128/JVI.00281-18 (2018).
Rerks-Ngarm, S. et al. Vaccination with ALVAC and AIDSVAX to forestall HIV-1 an infection in Thailand. N. Engl. J. Med. 361, 2209–2220 (2009).
Rolland, M. et al. Elevated HIV-1 vaccine efficacy in opposition to viruses with genetic signatures in Env V2. Nature 490, 417–420 (2012).
Jin, X. et al. Dramatic rise in plasma viremia after CD8(+) T cell depletion in simian immunodeficiency virus-infected macaques. J. Exp. Med. 189, 991–998 (1999).
Kostense, S. et al. Useful restoration of human immunodeficiency virus and Epstein-Barr virus-specific CD8(+) T cells throughout extremely lively antiretroviral remedy is related to a rise in CD4(+) T cells. Eur. J. Immunol. 32, 1080–1089 (2002).
Koup, R. A. et al. Temporal affiliation of mobile immune responses with the preliminary management of viremia in major human immunodeficiency virus kind 1 syndrome. J. Virol. 68, 4650–4655 (1994).
Lifson, J. D. et al. Position of CD8(+) lymphocytes accountable for simian immunodeficiency virus an infection and resistance to rechallenge after transient early antiretroviral therapy. J. Virol. 75, 10187–10199 (2001).
Matano, T. et al. Administration of an anti-CD8 monoclonal antibody interferes with the clearance of chimeric simian/human immunodeficiency virus throughout major infections of rhesus macaques. J. Virol. 72, 164–169 (1998).
Schmitz, J. E. et al. Management of viremia in simian immunodeficiency virus an infection by CD8+ lymphocytes. Science 283, 857–860 (1999).
Mattapallil, J. J. et al. Vaccination preserves CD4 reminiscence T cells throughout acute simian immunodeficiency virus problem. J. Exp. Med. 203, 1533–1541 (2006).
Nair, P. N. & Rossinsky, Ok. Crypt structure of tonsilla lingualis within the monkey, Macaca fascicularis. A correlated light- and scanning electron-microscopic research. Cell Tissue Res. 237, 619–627 (1984).
Gleason, E. B. A Handbook of Illnesses of the Nostril, Throat and Ear, 4th edn. (W. B. Saunders Firm, 1918).
Grey, H. Anatomy: Descriptive and Utilized, 18th edn. (Lea and Febiger, 1910).
Perry, M. & Whyte, A. Immunology of the tonsils. Immunol. Right now 19, 414–421 (1998).
McGhee, J. R., Mestecky, J., Elson, C. O. & Kiyono, H. Regulation of IgA synthesis and immune response by T cells and interleukins. J. Clin. Immunol. 9, 175–199 (1989).
Ogra, P. L., Faden, H. & Welliver, R. C. Vaccination methods for mucosal immune responses. Clin. Microbiol. Rev. 14, 430–445 (2001).
Lu, F. X. & Jacobson, R. S. Oral mucosal immunity and HIV/SIV an infection. J. Dent. Res. 86, 216–226 (2007).
Stahl-Hennig, C. et al. A single vaccination with attenuated SIVmac 239 through the tonsillar route confers partial safety in opposition to problem with SIVmac 251 at a distant mucosal website, the rectum. Entrance. Biosci 12, 2107–2123 (2007).
Stahl-Hennig, C. et al. Fast an infection of oral mucosal-associated lymphoid tissue with simian immunodeficiency virus. Science 285, 1261–1265 (1999).
Tenner-Racz, Ok. et al. Early safety in opposition to pathogenic virus an infection at a mucosal problem website after vaccination with attenuated simian immunodeficiency virus. Proc. Natl Acad. Sci. USA 101, 3017–3022 (2004).
Desvignes, C. et al. The murine buccal mucosa is an inductive website for priming class I-restricted CD8+ effector T cells in vivo. Clin. Exp. Immunol. 113, 386–393 (1998).
Etchart, N., Buckland, R., Liu, M. A., Wild, T. F. & Kaiserlian, D. Class I-restricted CTL induction by mucosal immunization with bare DNA encoding measles virus haemagglutinin. J. Gen. Virol. 78(Pt 7), 1577–1580 (1997).
Makitalo, B. et al. Enhanced mobile immunity and systemic management of SHIV an infection by mixed parenteral and mucosal administration of a DNA prime MVA enhance vaccine routine. J. Gen. Virol. 85, 2407–2419 (2004).
Sahoo, A. et al. A clade C HIV-1 vaccine protects in opposition to heterologous SHIV an infection by modulating IgG glycosylation and T helper response in macaques. Sci. Immunol. 7, eabl4102 (2022).
Velarde de la Cruz, E. et al. Oral vaccination approaches for Anti-SHIV immunity. Entrance. Immunol. 12, 702705 (2021).
Graham, B. S. et al. Part 1 security and immunogenicity analysis of a multiclade HIV-1 DNA candidate vaccine. J. Infect. Dis. 194, 1650–1660 (2006).
MacGregor, R. R. et al. First human trial of a DNA-based vaccine for therapy of human immunodeficiency virus kind 1 an infection: security and host response. J. Infect. Dis. 178, 92–100 (1998).
Robinson, H. L., Hunt, L. A. & Webster, R. G. Safety in opposition to a deadly influenza virus problem by immunization with a haemagglutinin-expressing plasmid DNA. Vaccine 11, 957–960 (1993).
Roy, M. J. et al. Induction of antigen-specific CD8+ T cells, T helper cells, and protecting ranges of antibody in people by particle-mediated administration of a hepatitis B virus DNA vaccine. Vaccine 19, 764–778 (2000).
Ulmer, J. B. et al. Heterologous safety in opposition to influenza by injection of DNA encoding a viral protein. Science 259, 1745–1749 (1993).
Xiang, Z. Q. et al. Vaccination with a plasmid vector carrying the rabies virus glycoprotein gene induces protecting immunity in opposition to rabies virus. Virology 199, 132–140 (1994).
Rahman, S. A. et al. Lymph node CXCR5+ NK cells affiliate with management of power SHIV an infection. JCI Perception 7, https://doi.org/10.1172/jci.insight.155601 (2022).
Ferlazzo, G. et al. Distinct roles of IL-12 and IL-15 in human pure killer cell activation by dendritic cells from secondary lymphoid organs. Proc. Natl Acad. Sci. USA 101, 16606–16611 (2004).
Wang, Y. et al. HIV-1-induced cytokines deplete homeostatic innate lymphoid cells and develop TCF7-dependent reminiscence NK cells. Nat. Immunol. 21, 274–286 (2020).
Moukambi, F. et al. Mucosal T follicular helper cells in SIV-infected rhesus macaques: contributing function of IL-27. Mucosal. Immunol. 12, 1038–1054 (2019).
Gasper, M. A. et al. Nonpathogenic SIV and pathogenic HIV infections affiliate with disparate innate cytokine signatures in response to Mycobacterium bovis BCG. PLoS ONE 11, e0158149 (2016).
Vagenas, P. et al. Tonsillar software of AT-2 SIV affords partial safety in opposition to rectal problem with SIVmac239. J. Acquir. Immune Defic. Syndr. 52, 433–442 (2009).
Stahl-Hennig, C. et al. Atraumatic oral spray immunization with replication-deficient viral vector vaccines. J. Virol. 81, 13180–13190 (2007).
Letvin, N. L. et al. Heterologous envelope immunogens contribute to AIDS vaccine safety in rhesus monkeys. J. Virol. 78, 7490–7497 (2004).
Mascola, J. R. et al. Neutralizing antibodies elicited by immunization of monkeys with DNA plasmids and recombinant adenoviral vectors expressing human immunodeficiency virus kind 1 proteins. J. Virol. 79, 771–779 (2005).
Staib, C. et al. Transient host vary choice for genetic engineering of modified vaccinia virus Ankara. Biotechniques 28, 1137–1142 (2000). 1144-1136, 1148.
Kremer, M. et al. Simple and environment friendly protocols for working with recombinant vaccinia virus MVA. Strategies Mol. Biol. 890, 59–92 (2012).
Meyer, H., Sutter, G. & Mayr, A. Mapping of deletions within the genome of the extremely attenuated vaccinia virus MVA and their affect on virulence. J. Gen. Virol. 72(Pt 5), 1031–1038 (1991).
Wyatt, L. S. et al. Elucidating and minimizing the loss by recombinant vaccinia virus of human immunodeficiency virus gene expression ensuing from spontaneous mutations and constructive choice. J. Virol. 83, 7176–7184 (2009).
Lee, E. M. et al. Molecular strategies for analysis of virological standing of nonhuman primates challenged with simian immunodeficiency or simian-human immunodeficiency viruses. J. Virol. Strategies 163, 287–294 (2010).
Romano, J. W. et al. Quantitative analysis of simian immunodeficiency virus an infection utilizing NASBA know-how. J. Virol. Strategies 86, 61–70 (2000).
Kader, M., Bixler, S., Piatak, M., Lifson, J. & Mattapallil, J. J. Anti-retroviral remedy fails to revive the extreme Th-17: Tc-17 imbalance noticed in peripheral blood throughout simian immunodeficiency virus an infection. J. Med. Primatol. 38(Suppl 1), 32–38 (2009).
Kader, M. et al. Antiretroviral remedy previous to acute viral replication preserves CD4 T cells within the periphery however not in rectal mucosa throughout acute simian immunodeficiency virus an infection. J. Virol. 82, 11467–11471 (2008).
Kuwata, T. et al. Infectious molecular clones from a simian immunodeficiency virus-infected rapid-progressor (RP) macaque: proof of differential number of RP-specific envelope mutations in vitro and in vivo. J. Virol. 80, 1463–1475 (2006).
Mattapallil, J. J., Hill, B., Douek, D. C. & Roederer, M. Systemic vaccination prevents the full destruction of mucosal CD4 T cells throughout acute SIV problem. J. Med. Primatol. 35, 217–224 (2006).
Mattapallil, J. J., Reay, E. & Dandekar, S. An early growth of CD8alphabeta T cells, however depletion of resident CD8alphaalpha T cells, happens within the intestinal epithelium throughout major simian immunodeficiency virus an infection. Aids 14, 637–646 (2000).
Moore, A. C., Bixler, S. L., Lewis, M. G., Verthelyi, D. & Mattapallil, J. J. Mucosal and peripheral Lin- HLA-DR+ CD11c/123- CD13+ CD14- mononuclear cells are preferentially contaminated throughout acute simian immunodeficiency virus an infection. J. Virol. 86, 1069–1078 (2012).
Bixler, S. L., Sandler, N. G., Douek, D. C. & Mattapallil, J. J. Suppressed Th17 ranges correlate with elevated PIAS3, SHP2, and SOCS3 expression in CD4 T cells throughout acute simian immunodeficiency virus an infection. J. Virol. https://doi.org/10.1128/JVI.00600-13 (2013).
Eberly, M. D. et al. Elevated IL-15 manufacturing is related to increased susceptibility of reminiscence CD4 T cells to simian immunodeficiency virus throughout acute an infection. J. Immunol. 182, 1439–1448 (2009).
George, J. et al. Early short-term antiretroviral remedy is related to a lowered prevalence of CD8(+)FoxP3(+) T cells in simian immunodeficiency virus-infected controller rhesus macaques. AIDS Res. Hum. Retroviruses 27, 763–775 (2011).
Kader, M. et al. Alpha4(+)beta7(hello)CD4(+) reminiscence T cells harbor most Th-17 cells and are preferentially contaminated throughout acute SIV an infection. Mucosal. Immunol. 2, 439–449 (2009).
Onabajo, O. O., George, J., Lewis, M. G. & Mattapallil, J. J. Rhesus macaque lymph node PD-1(hello)CD4(+) T cells specific excessive ranges of CXCR5 and IL-21 and show a CCR7(lo)ICOS(+)Bcl6(+) T-follicular helper (Tfh) cell phenotype. PLoS ONE 8, e59758 (2013).
Demberg, T. et al. Dynamics of reminiscence B-cell populations in blood, lymph nodes, and bone marrow throughout antiretroviral remedy and envelope boosting in simian immunodeficiency virus SIVmac251-infected rhesus macaques. J. Virol. 86, 12591–12604 (2012).
Montefiori, D. C. & Measuring, H. I. V. neutralization in a luciferase reporter gene assay. Strategies Mol. Biol. 485, 395–405 (2009).
Shen, X. et al. HIV-1 vaccine sequences impression V1V2 antibody responses: a comparability of two poxvirus prime gp120 enhance vaccine regimens. Sci. Rep. 10, 2093 (2020).
Tomaras, G. D. et al. Polyclonal B cell responses to conserved neutralization epitopes in a subset of HIV-1-infected people. J. Virol. 85, 11502–11519 (2011).
Gomez-Roman, V. R. et al. A simplified methodology for the fast fluorometric evaluation of antibody-dependent cell-mediated cytotoxicity. J. Immunol. Strategies 308, 53–67 (2006).
George, J. et al. Prior publicity to Zika virus considerably enhances peak dengue-2 viremia in rhesus macaques. Sci. Rep. 7, 10498 (2017).
Valiant, W. G. et al. Simultaneous coinfection of macaques with Zika and dengue viruses doesn’t improve acute plasma viremia however results in activation of monocyte subsets and biphasic launch of pro-inflammatory cytokines. Sci. Rep. 9, 7877 (2019).
Mattapallil, J. J. et al. Huge an infection and lack of reminiscence CD4+ T cells in a number of tissues throughout acute SIV an infection. Nature 434, 1093–1097 (2005).
Pitcher, C. J. et al. Improvement and homeostasis of T cell reminiscence in rhesus macaque. J. Immunol. 168, 29–43 (2002).
Maecker, H. T. et al. Use of overlapping peptide mixtures as antigens for cytokine movement cytometry. J. Immunol. Strategies 255, 27–40 (2001).
Perfetto, S. P. et al. Amine-reactive dyes for useless cell discrimination in mounted samples. Curr. Protoc. Cytom. 53, 9–34 (2010).
Roederer, M., Nozzi, J. L. & Nason, M. C. SPICE: exploration and evaluation of post-cytometric advanced multivariate datasets. Cytometry A 79, 167–174 (2011).
Klasse, P. J. & Moore, J. P. Reappraising the worth of HIV-1 vaccine correlates of safety analyses. J. Virol. 96, e0003422 (2022).
